ImageneBio, Inc. (IMA)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
5.90 USD
+0.12
(2.076%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.52 -0.38 (-0.380%) ⇩ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:56 p.m. EDT
ImageneBio, Inc. (IMA) is currently in a highly volatile and bearish position, with a short-term price forecast indicating a significant decline of approximately 10.9%. The stock has been trading below its 50-day average and 200-day average, suggesting a lack of momentum and potential for further downside. The company's fundamentals are weak, with negative earnings and a high debt-to-equity ratio, indicating financial instability. Additionally, there are no recent dividend payouts, which makes it unsuitable for dividend-focused investors. The recent news headlines include both positive and negative developments, but the overall sentiment is mixed, with a focus on legal and regulatory risks. Given the current price and fundamentals, it is not advisable to invest in IMA for either short-term or long-term purposes. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.145463 |
| MSTL | 0.195172 |
| AutoETS | 0.196981 |
| AutoARIMA | 0.196984 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 28.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.188 |
| Excess Kurtosis | -0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.235 |
| Revenue per Share | 0.147 |
| Market Cap | 65,991,472 |
| Forward P/E | -1.75 |
| Previous Name | Inmagene Biopharmaceuticals Co. Ltd. |
| Website | https://www.inmagenebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5774854 |
| Address1 | 12,526 High Bluff Drive |
| Address2 | Suite 345 |
| All Time High | 451.32 |
| All Time Low | 3.94 |
| Ask | 5.95 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,960,000 |
| Average Daily Volume3 Month | 356,503 |
| Average Volume | 356,503 |
| Average Volume10Days | 1,960,000 |
| Bid | 6.04 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 11.907 |
| City | San Diego |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.9 |
| Current Ratio | 12.488 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.05 |
| Day Low | 5.63 |
| Debt To Equity | 2.235 |
| Display Name | ImageneBio |
| Ebitda | -48,052,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.381 |
| Enterprise To Revenue | -82.978 |
| Enterprise Value | -66,382,528 |
| Eps Current Year | -3.855 |
| Eps Forward | -3.365 |
| Eps Trailing Twelve Months | -9.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.00334 |
| Fifty Day Average Change | -0.10333967 |
| Fifty Day Average Change Percent | -0.017213697 |
| Fifty Two Week Change Percent | -57.74854 |
| Fifty Two Week High | 18.0 |
| Fifty Two Week High Change | -12.1 |
| Fifty Two Week High Change Percent | -0.67222226 |
| Fifty Two Week Low | 3.94 |
| Fifty Two Week Low Change | 1.96 |
| Fifty Two Week Low Change Percent | 0.49746194 |
| Fifty Two Week Range | 3.94 - 18.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,765,400,000 |
| Float Shares | 6,266,505 |
| Forward Eps | -3.365 |
| Forward P E | -1.7533432 |
| Free Cashflow | -18,874,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 800,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15833999 |
| Held Percent Institutions | 0.49517 |
| Implied Shares Outstanding | 11,184,995 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,660,800 |
| Last Split Factor | 1:12 |
| Long Business Summary | ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. |
| Long Name | ImageneBio, Inc. |
| Market | us_market |
| Market Cap | 65,991,472 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_689254445 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -52,395,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 65,767,770 |
| Number Of Analyst Opinions | 2 |
| Open | 5.78 |
| Operating Cashflow | -47,844,000 |
| Operating Margins | -60.56375 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 345 6265 |
| Post Market Change | -0.3800001 |
| Post Market Change Percent | -6.44068 |
| Post Market Price | 5.52 |
| Post Market Time | 1,776,470,370 |
| Prev Name | Inmagene Biopharmaceuticals Co. Ltd. |
| Previous Close | 5.78 |
| Price Eps Current Year | -1.5304799 |
| Price Hint | 2 |
| Price To Book | 0.49550688 |
| Price To Sales Trailing12 Months | 82.48934 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.164 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.12 |
| Regular Market Change Percent | 2.07612 |
| Regular Market Day High | 6.05 |
| Regular Market Day Low | 5.63 |
| Regular Market Day Range | 5.63 - 6.05 |
| Regular Market Open | 5.78 |
| Regular Market Previous Close | 5.78 |
| Regular Market Price | 5.9 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 62,817 |
| Return On Assets | -0.35858002 |
| Return On Equity | -0.68913 |
| Revenue Per Share | 0.147 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 11,184,995 |
| Shares Percent Shares Out | 0.0346 |
| Shares Short | 378,159 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 378,568 |
| Short Name | ImageneBio, Inc. |
| Short Ratio | 10.26 |
| Source Interval | 15 |
| State | CA |
| Symbol | IMA |
| Target High Price | 30.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 16.0 |
| Target Median Price | 16.0 |
| Total Cash | 135,348,992 |
| Total Cash Per Share | 12.101 |
| Total Debt | 2,975,000 |
| Total Revenue | 800,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.877085 |
| Two Hundred Day Average Change | -2.9770846 |
| Two Hundred Day Average Change Percent | -0.33536738 |
| Type Disp | Equity |
| Volume | 62,817 |
| Website | https://www.inmagenebio.com |
| Zip | 92,130 |